Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah Eddin Al-Batran*, Ralf D. Hofheinz, Claudia Pauligk, Hans Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Johannes Meiler, Nils Homann, Sylvie Lorenzen, Harald Schmalenberg, Stephan Probst, Michael Koenigsmann, Matthias Egger, Nicole Prasnikar, Karel Caca, Jörg Trojan, Uwe M. Martens, Andreas Block, Wolfgang Fischbach, Rolf MahlbergMichael Clemens, Gerald Illerhaus, Katja Zirlik, Dirk M. Behringer, Wolff Schmiegel, Michael Pohl, Michael Heike, Ulrich Ronellenfitsch, Martin Schuler, Wolf O. Bechstein, Alfred Königsrainer, Timo Gaiser, Peter Schirmacher, Wael Hozaeel, Alexander Reichart, Thorsten O. Goetze, Mark Sievert, Elke Jäger, Stefan Mönig, Andrea Tannapfel

*Corresponding author for this work
269 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences